Cspc Pharmaceutical traded at 7.79 this Thursday June 30th, increasing 0.16 or 2.10 percent since the previous trading session. Looking back, over the last four weeks, Cspc Pharmaceutical gained 7.26 percent. Over the last 12 months, its price fell by 29.44 percent. Looking ahead, we forecast Cspc Pharmaceutical to be priced at 7.57 by the end of this quarter and at 6.93 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Sino Biopharmaceutical Ltd 4.97 0.28 5.97% -33.47%
Jiangsu Hengrui Me. 38.80 1.71 4.61% -42.01%

Indexes Price Day Year
HK50 21860 -137.10 -0.62% -22.79%

Cspc Pharmaceutical
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.